Michael Payette is a Dermatology physician. OpenAlex indexes 35 publications with 1,399 citations (h-index 14).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1 Willowbrook Rd Ste 2
Cromwell, CT 064161745
Telephone
860-322-2222Provider last certified this registry record 26 Jul 2023.
Industry payments
42 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UCB, Inc.Program year2025182 payments$137,665openpaymentsdata.cms.gov ↗
- ABBVIE INC.Program year2025162 payments$137,605openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202560 payments$93,048openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Dermatology
38.4%Interleukin-4 Receptor alpha Antagonist18.6%Dupixent Syringe60%Dupixent Pen40%Part D≥14 patientsCorticosteroid10.1%Triamcinolone Acetonide92%Halobetasol Propionate8%Part D<11 patients+ 5 more classes in this area
Anti-infectives
20.6%Tetracycline-class Drug7.9%Doxycycline Hyclate61%Doxycycline Monohydrate39%Part D≥41 patientsAzole Antifungal6.7%Ketoconazole77%Itraconazole23%Part D<11 patients+ 3 more classes in this area
Cancer & immunology
14.2%Interleukin-23 Antagonist2.5%Skyrizi Pen59%Tremfya41%Part D<11 patientsTNF inhibitor2.4%Humira(Cf) Pen61%Enbrel Sureclick39%Part D<11 patients+ 6 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.
PubMed
2025 - A Case of Grover’s Disease Secondary to Brodalumab Therapy for Psoriasis
Journal of Psoriasis and Psoriatic Arthritis
2020
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”